Harbour Trust & Investment Management Co Sells 332 Shares of Eli Lilly and Company $LLY

Harbour Trust & Investment Management Co lessened its holdings in Eli Lilly and Company (NYSE:LLY) by 6.1% during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 5,103 shares of the company’s stock after selling 332 shares during the period. Harbour Trust & Investment Management Co’s holdings in Eli Lilly and Company were worth $3,978,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the business. WestEnd Advisors LLC grew its holdings in shares of Eli Lilly and Company by 210.0% in the first quarter. WestEnd Advisors LLC now owns 31 shares of the company’s stock valued at $26,000 after purchasing an additional 21 shares in the last quarter. Wealth Preservation Advisors LLC purchased a new position in Eli Lilly and Company during the first quarter worth $27,000. Citizens National Bank Trust Department boosted its stake in Eli Lilly and Company by 180.0% during the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company’s stock worth $35,000 after buying an additional 27 shares during the period. Financial Gravity Asset Management Inc. bought a new stake in shares of Eli Lilly and Company during the first quarter worth $40,000. Finally, TD Capital Management LLC lifted its position in shares of Eli Lilly and Company by 129.2% during the first quarter. TD Capital Management LLC now owns 55 shares of the company’s stock worth $46,000 after purchasing an additional 31 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, EVP Daniel Skovronsky purchased 1,000 shares of Eli Lilly and Company stock in a transaction that occurred on Tuesday, August 12th. The stock was purchased at an average price of $634.40 per share, with a total value of $634,400.00. Following the completion of the acquisition, the executive vice president owned 137,660 shares of the company’s stock, valued at approximately $87,331,504. This trade represents a 0.73% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Gabrielle Sulzberger purchased 117 shares of Eli Lilly and Company stock in a transaction that occurred on Tuesday, August 12th. The stock was acquired at an average cost of $641.18 per share, with a total value of $75,018.06. Following the acquisition, the director directly owned 2,703 shares of the company’s stock, valued at $1,733,109.54. The trade was a 4.52% increase in their position. The disclosure for this purchase can be found here. Insiders acquired a total of 4,514 shares of company stock valued at $2,894,841 over the last three months. Insiders own 0.14% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the stock. Leerink Partners reiterated a “market perform” rating and issued a $715.00 target price on shares of Eli Lilly and Company in a report on Thursday, August 7th. Morgan Stanley dropped their target price on Eli Lilly and Company from $1,028.00 to $1,023.00 and set an “overweight” rating on the stock in a research report on Friday, October 3rd. Weiss Ratings reiterated a “hold (c+)” rating on shares of Eli Lilly and Company in a research report on Wednesday, October 8th. HSBC boosted their price target on Eli Lilly and Company from $700.00 to $800.00 in a report on Wednesday, October 1st. Finally, Deutsche Bank Aktiengesellschaft reduced their target price on Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating for the company in a research note on Monday, August 11th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and ten have assigned a Hold rating to the stock. According to data from MarketBeat.com, Eli Lilly and Company has a consensus rating of “Moderate Buy” and a consensus price target of $948.06.

Eli Lilly and Company Price Performance

Shares of NYSE LLY opened at $818.60 on Tuesday. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $937.00. The firm has a market capitalization of $774.77 billion, a PE ratio of 53.50, a price-to-earnings-growth ratio of 1.18 and a beta of 0.47. The stock’s 50-day simple moving average is $743.43 and its 200-day simple moving average is $765.54.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. During the same quarter in the previous year, the company posted $3.92 earnings per share. The company’s revenue for the quarter was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, equities research analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.